CC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into The Chemours Company and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of The Chemours Company ("Chemours" or "the Company") (NYSE:CC). Investors who purchased Chemours securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CC.
The Chemours Company Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - CC
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. Chemours issued a press release on August 1, 2024, reporting its financial results for the second quarter of 2024.
CC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into The Chemours Company and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of The Chemours Company ("Chemours" or "the Company") (NYSE:CC). Investors who purchased Chemours securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CC.
ATTENTION CC SHAREHOLDERS: Investors who lost money on The Chemours Company are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. Chemours issued a press release on August 1, 2024, reporting its financial results for the second quarter of 2024.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Chemours Company - CC
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / 2024 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company ("Chemours" or the "Company") (NYSE:CC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Chemours (CC) Earnings Miss, Revenues Beat Estimates in Q2
Chemours' (CC) earnings miss estimates in the second quarter due to lower selling prices.
The Chemours Company (CC) Q2 2024 Earnings Call Transcript
The Chemours Company (NYSE:CC ) Q2 2024 Earnings Conference Call August 2, 2024 8:00 AM ET Company Participants Brandon Ontjes - VP of IR Denise Dignam - President and CEO Shane Hostetter - SVP, CFO & Principal Accounting Officer Conference Call Participants John McNulty - BMO Capital Markets Mike Leithead - Barclays John Roberts - Mizuho Josh Spector - UBS Financial Hassan Ahmed - Alembic Global Advisors Laurence Alexander - Jefferies Arun Viswanathan - RBC Capital Markets Vincent Andrews - Morgan Stanley John McNulty - BMO Capital Markets Operator Good morning. My name is Regina and I will be your conference operator today.
Chemours (CC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Misses Q2 Earnings Estimates
Chemours (CC) came out with quarterly earnings of $0.38 per share, missing the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.10 per share a year ago.
Earnings Preview: Chemours (CC) Q2 Earnings Expected to Decline
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours Rises as UBS Upgrades Stock To 'Buy'
The Chemours Co. (CC) shares gained in intraday trading Tuesday following an upgrade from UBS analysts, who said investors have been too negative on the chemical maker's stock.
Chemours (CC) Soars 5.5%: Is Further Upside Left in the Stock?
Chemours (CC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
